Integrated phase I pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection
AQST-109 delivered epinephrine with PK and PD results within the bracketed range of approved intramuscular products. AQST-109 has promise as an innovative, needle-free, nondevice, portable, and orally delivered alternative for first-line treatment of type I allergic reactions, including anaphylaxis.
Authors
- Matthew Greenhawt (ORCID: https://orcid.org/0000-0002-2365-9372)
- Steve Wargacki
- Carlos A. Camargo (ORCID: https://orcid.org/0000-0002-5071-7654)
- Jay R. Lieberman (ORCID: https://orcid.org/0000-0002-1374-8929)
- Carl Kraus
- David M. Golden
Institutions
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- MedStar Franklin Square Medical Center (US)
- Massachusetts General Hospital (US)
- Children's Hospital Colorado (US)
- Aquestive (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1016/j.anai.2025.01.006
- Citations
- 6
- Primary Topic
- Analytical Chemistry and Chromatography
- Type
- article
- Field-Weighted Citation Impact
- 4.54